David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusettes, 02139, USA.
Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, Kansas, 66047, USA.
AAPS J. 2023 Aug 17;25(5):81. doi: 10.1208/s12248-023-00844-z.
mRNA vaccines can be translated into protein antigens, in vivo, to effectively induce humoral and cellular immunity against these proteins. While current mRNA vaccines have generated potent immune responses, the need for ultracold storage conditions (- 80 °C) and healthcare professionals to administer the vaccine through the parenteral route has somewhat limited their distribution in rural areas and developing countries. Overcoming these challenges stands to transform future deployment of mRNA vaccines. In this study, we developed an mRNA vaccine that can trigger a systemic immune response through administration via the gastrointestinal (GI) tract and is stable at 4 °C. A library of cationic branched poly(β-amino ester) (PBAE) polymers was synthesized and characterized, from which a polymer with high intracellular mRNA delivery efficiency and immune stimulation capacity was down-selected. mRNA vaccines made with the lead polymer-elicited cellular and humoral immunity in mice. Furthermore, lyophilization conditions of the formulation were optimized to enable storage under refrigeration. Our results suggest that PBAE nanoparticles are potent mRNA delivery platforms that can elicit B cell and T cell activation, including antigen-specific cellular and humoral responses. This system can serve as an easily administrable, potent oral mRNA vaccine.
mRNA 疫苗可在体内翻译成蛋白质抗原,有效诱导针对这些蛋白质的体液和细胞免疫。虽然目前的 mRNA 疫苗已经产生了强烈的免疫反应,但由于需要超低温储存条件(-80°C)和医疗保健专业人员通过注射途径来管理疫苗,它们在农村地区和发展中国家的分发受到了一定限制。克服这些挑战有望改变未来 mRNA 疫苗的部署方式。在这项研究中,我们开发了一种 mRNA 疫苗,它可以通过胃肠道(GI)途径给药引发全身性免疫反应,并且在 4°C 下稳定。合成并表征了一系列阳离子支化聚(β-氨基酯)(PBAE)聚合物,从中筛选出一种具有高细胞内 mRNA 传递效率和免疫刺激能力的聚合物。用先导聚合物制备的 mRNA 疫苗在小鼠中引发了细胞和体液免疫。此外,优化了制剂的冻干条件,使其能够在冷藏条件下储存。我们的结果表明,PBAE 纳米颗粒是有效的 mRNA 递送平台,可引发 B 细胞和 T 细胞激活,包括抗原特异性细胞和体液反应。该系统可作为一种易于管理的、有效的口服 mRNA 疫苗。